DND PharmaTech Inc
KOSDAQ:347850
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
DND PharmaTech Inc
Accumulated Depreciation
DND PharmaTech Inc
Accumulated Depreciation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accumulated Depreciation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
D
|
DND PharmaTech Inc
KOSDAQ:347850
|
Accumulated Depreciation
-₩8.2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Accumulated Depreciation
-₩760.7B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-15%
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Accumulated Depreciation
-₩6.6B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Accumulated Depreciation
-₩12.5B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-34%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Accumulated Depreciation
-₩12B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Accumulated Depreciation
-₩7.6B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
DND PharmaTech Inc
Glance View
DND PharmaTech Inc is a KR-based company operating in Biotechnology industry. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2024-05-02. DND Pharmatech Inc is a Korea-based clinical-stage biotech company mainly engaged in the research and development in medicines. The firm's product pipeline mainly focuses on indications including metabolic disease, neurodegenerative and fibrotic diseases. In addition, the Company is engaged in the research and development of therapeutic medicines used for diabetes, obesity and nonalcoholic steatohepatitis as well as others.
See Also
What is DND PharmaTech Inc's Accumulated Depreciation?
Accumulated Depreciation
-8.2B
KRW
Based on the financial report for Dec 31, 2024, DND PharmaTech Inc's Accumulated Depreciation amounts to -8.2B KRW.
What is DND PharmaTech Inc's Accumulated Depreciation growth rate?
Accumulated Depreciation CAGR 1Y
8%
Over the last year, the Accumulated Depreciation growth was 8%.
